Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wesche

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2023
PBPK modeling of ivermectin-Considerations for the purpose of developing alternative routes to optimize its safety profileKaren Rowland Yeo, David Wesche
Clinical and Translational Science|March 27, 2020
Optimizing COVID-19 Candidate Therapeutics: Thinking Without BordersCraig R Rayner, Patrick F Smith, Kevin Hershberger, et al.
Clinical Pharmacokinetics|September 8, 2010
A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentinHoward N Bockbrader, David Wesche, Raymond Miller, et al.
Epilepsia|May 19, 2015
Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsyDwain Tolbert, James Cloyd, Victor Biton, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 5, 2019
Model-Informed Assessment of Anti-Infectives for Young Children in Low- and Middle-Income CountriesPing Zhao, Jonathan Arm, Lyou-Fu Ma, et al.
Annual Review of Pharmacology and Toxicology|October 10, 2017
Model-Informed Drug Development for Malaria TherapeuticsKayla Ann Andrews, David Wesche, James McCarthy, et al.
Clinical and Translational Science|December 16, 2020
Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug DevelopmentKayla Ann Andrews, Joel S Owen, James McCarthy, et al.
Clinical Pharmacology and Therapeutics|June 13, 2020
Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK ModelingKaren Rowland Yeo, Mian Zhang, Xian Pan, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2022
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverriniChristine Falcoz, Serge Guzy, Jana Kovač, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 13, 2022
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverriniChristine Falcoz, Serge Guzy, Jana Kovač, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2023
PBPK modeling of ivermectin-Considerations for the purpose of developing alternative routes to optimize its safety profileKaren Rowland Yeo, David Wesche
Clinical and Translational Science|March 27, 2020
Optimizing COVID-19 Candidate Therapeutics: Thinking Without BordersCraig R Rayner, Patrick F Smith, Kevin Hershberger, et al.
Clinical Pharmacokinetics|September 8, 2010
A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentinHoward N Bockbrader, David Wesche, Raymond Miller, et al.
Epilepsia|May 19, 2015
Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsyDwain Tolbert, James Cloyd, Victor Biton, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 5, 2019
Model-Informed Assessment of Anti-Infectives for Young Children in Low- and Middle-Income CountriesPing Zhao, Jonathan Arm, Lyou-Fu Ma, et al.
Annual Review of Pharmacology and Toxicology|October 10, 2017
Model-Informed Drug Development for Malaria TherapeuticsKayla Ann Andrews, David Wesche, James McCarthy, et al.
Clinical and Translational Science|December 16, 2020
Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug DevelopmentKayla Ann Andrews, Joel S Owen, James McCarthy, et al.
Clinical Pharmacology and Therapeutics|June 13, 2020
Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK ModelingKaren Rowland Yeo, Mian Zhang, Xian Pan, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2022
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverriniChristine Falcoz, Serge Guzy, Jana Kovač, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 13, 2022
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverriniChristine Falcoz, Serge Guzy, Jana Kovač, et al.
Pageof 3